Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 11/20 | 1.00 |
| ▸ | UCHL1 | P09936 | 1/20 | 1.00 |
| ▸ | USP5 | P45974 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 0.72 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317674 | 1.00 | USP9X (1.00) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL1317669 | 1.00 | USP9X (1.00) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL882501 | 1.00 | USP9X (1.00) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL21592386 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864886 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864885 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL1315701 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315698 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315700 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315703 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200325130-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | UNIV YALE (US) | 2020-10-15 | — | — | US | disclosed |
| US-20190105341-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | THE BOARD OF TRUSTEE OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-04-11 | — | — | US | disclosed |
| US-10149860-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | Board of Trustees of the Leland Stanford Junior University, Stanford University Office of Technology Licensing (US) | 2018-12-11 | — | — | US | disclosed |
| EP-3370715-A1 | PROTEOLYSIS TARGETING CHIMERA COMPOUNDS AND METHODS OF PREPARING AND USING SAME | Yale University (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180186785-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | UNIV YALE (US) | 2018-07-05 | — | — | US | disclosed |
| US-9938264-B2 | Proteolysis targeting chimera compounds and methods of preparing and using same | YALE UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2017079267-A1 | PROTEOLYSIS TARGETING CHIMERA COMPOUNDS AND METHODS OF PREPARING AND USING SAME | YALE UNIVERSITY (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121321-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | YALE UNIVERSITY | 2017-05-04 | — | — | US | disclosed |
| US-20160151407-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-06-02 | — | — | US | disclosed |
| US-9289448-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150174150-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, LLC (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10149860-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | USP9X, PSEN1, PSEN2 | USP9X 1/4885UCHL1 24/4885USP5 25/4885 |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | VHL, PRKDC, POLR1C | USP9X 3737/4885UCHL1 3312/4885USP5 3130/4885 |
| US-20200325130-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | USP9X 203/4885UCHL1 9/4885USP5 31/4885 |
| US-20170121321-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | USP9X 203/4885UCHL1 9/4885USP5 31/4885 |
| US-20160151407-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | USP9X, PSEN1, PSEN2 | USP9X 1/4885UCHL1 24/4885USP5 25/4885 |
| US-20180186785-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | USP9X 203/4885UCHL1 9/4885USP5 31/4885 |
| US-20190105341-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | USP9X, PSEN1, PSEN2 | USP9X 1/4885UCHL1 24/4885USP5 25/4885 |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | STAT3, STAT1, STAT5B | USP9X 3930/4885UCHL1 4553/4885USP5 4112/4885 |
| US-20150174150-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | USP9X, PSEN1, PSEN2 | USP9X 1/4885UCHL1 24/4885USP5 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.